Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Mesothelioma, Malignant 2Phase IB 1Ovarian Neoplasms 1Non Hematologic Cancers 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Carcinoma, Ovarian Epithelial 1Carcinoma, Endometrioid 1

Interventions

Gemcitabine 170130-nm albumin-bound paclitaxel 54Albumin-Bound Paclitaxel 42Oxaliplatin 33Fluorouracil 32pembrolizumab 30Capecitabine 30Leucovorin 28Irinotecan 28Radiotherapy 25Nivolumab 22Erlotinib Hydrochloride 21Taxes 19Cisplatin 19Bevacizumab 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Radiosurgery 11Ipilimumab 11Cyclophosphamide 11Drug Therapy 10Carboplatin 10Biopsy 10Paclitaxel 9Docetaxel 9Cetuximab 9trametinib 8olaparib 8durvalumab 8Sorafenib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Pancreatic Neoplasms × defactinib × Clear all
NCT03875820 2026-03-10

FRAME

Institute of Cancer Research, United Kingdom

Phase 1 Active not recruiting
87 enrolled
Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Endometrioid

NCT02546531 2021-07-20

Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

Washington University School of Medicine

Phase 1 Completed
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡